Journal ArticleOPEN ACCESS

Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors

  • Thomas A
  • Ma W
  • Wang Y
New England Journal of Medicine (2021) 384(6) 581-583
DOI: 10.1056/nejmc2031717
78Citations
Citations of this article
52Readers
Mendeley users who have this article in their library.

Abstract

Ustekinumab for Refractory Colitis Two patients in whom severe refractory autoimmune colitis developed after cancer treatment with immune checkpoint inhibitors had a response to a course of subcuta...

Cite

CITATION STYLE

APA

Thomas, A. S., Ma, W., & Wang, Y. (2021). Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors. New England Journal of Medicine, 384(6), 581–583. https://doi.org/10.1056/nejmc2031717

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free